『Top of the Morning』のカバーアート

Top of the Morning

Top of the Morning

著者： Mint - HT Smartcast
無料で聴く

このコンテンツについて

 Top of the Morning is a daily podcast hosted by Nelson John, in which we bring you all the action from the global markets and the business world to kick-start your day on a well-informed note. This is a Mint production, brought to you by HT Smartcast 個人ファイナンス 政治・政府 経済学
エピソード
  • F-35 Set to Fly Home | Nipah Scare Returns | Vedanta Called a ‘Parasite’ in Explosive Report | India’s $700M Cancer Bet

    F-35 Set to Fly Home | Nipah Scare Returns | Vedanta Called a ‘Parasite’ in Explosive Report | India’s $700M Cancer Bet
    2025/07/11
    Welcome to Top of the Morning by Mint.. I’m Nelson John and here are today’s top stories.Jet-Lagged in Kerala, may finally leave for home Jet-Lagged in Kerala, may finally leave for home A $115 million British F-35B stealth jet has been grounded at Thiruvananthapuram airport since June 14 after bad weather forced it to divert from the HMS Prince of Wales. While engineers work on repairs, the jet has turned into a social media sensation. Kerala Tourism joined the fun with a viral post: “Kerala is such an amazing place, I don’t want to leave.” Cartoons have popped up showing the jet enjoying chai and snacks under palm trees. The UK Defence Ministry has dismissed rumors about dismantling and flying it back via cargo. The aircraft is expected to take off again as early as next week. Nipah Returns: Kerala on Guard Kerala is back on high alert after two confirmed cases of the deadly Nipah virus—one fatal. An 18-year-old girl from Malappuram died, while a 38-year-old woman from Palakkad is undergoing treatment. Nearly 500 people are on the contact list, with 29 in the highest-risk category. Despite this, no new cases have been reported, and containment zones in Malappuram have been lifted. A central health team is on the ground coordinating efforts. Nipah is a zoonotic virus with no vaccine, but Kerala’s public health system has managed past outbreaks with early detection and isolation. Vedanta Called a ‘Parasite’ in Explosive Report In a scathing 87-page report, US-based Viceroy Research accused Vedanta Resources Ltd (VRL) of draining its Indian arm, Vedanta Ltd (VEDL), through aggressive dividend extraction, shady internal loans, and dubious brand fees. The report calls VRL a “parasite” with no meaningful operations of its own, relying on the Mumbai-listed company to survive. It highlights over $8 billion in dividends paid by VEDL despite falling cash flows, unexplained interest costs, and $1 billion in suspect loans. Viceroy also flagged flashy project announcements with little follow-through, a revolving door of senior execs, and 107 legal disclosures since 2022—far more than peers like Tata Steel. The takeaway? A pattern of poor governance and financial engineering. Tax Relief for Green Investors The Indian Renewable Energy Development Agency (IREDA) just received a big push from the finance ministry. Its bonds are now classified as ‘long-term specified assets’ under Section 54EC of the Income Tax Act. Translation: investors can save capital gains tax by investing up to ₹50 lakh annually in these bonds. The proceeds will be used exclusively for revenue-generating renewable energy projects. IREDA chairman Pradip Kumar Das hailed the move as a “pivotal moment” for green finance. The company posted a strong Q4 profit rise but saw a dip in Q1 earnings. Nonetheless, its stock ended 2.26% higher. Glenmark’s $700 Million Global Leap Glenmark Pharmaceuticals has struck gold with the biggest outlicensing deal in Indian pharma history. Its US-based unit, Ichnos Glenmark Innovation (IGI), has licensed a breakthrough blood cancer drug to AbbVie for $700 million upfront, with total potential payouts of $1.93 billion. The drug, ISB 2001, is a trispecific antibody targeting multiple myeloma—an aggressive blood cancer that resists conventional treatments. The therapy is still in early trials but has already received orphan and fast track designations from the FDA. Glenmark will retain rights in India and emerging markets, while AbbVie takes it global. “This puts India on the world map,” said Glenmark MD Glenn Saldanha. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    8 分
  • Vedanta Exposed? | Brazil’s 50% Tariff Blow | $250 US Visa Fee | 200% Pharma Tariff?

    Vedanta Exposed? | Brazil’s 50% Tariff Blow | $250 US Visa Fee | 200% Pharma Tariff?
    2025/07/10
    Welcome to Top of the Morning by Mint.. I’m Nelson John and here are today’s top stories. Trump Hits Brazil With 50% Tariff In a fiery escalation, U.S. President Donald Trump announced a 50% tariff on all Brazilian imports starting August 1. The move follows a diplomatic spat with Brazil’s President Lula da Silva, who called Trump an “unwanted emperor.” Trump fired back with a sharply worded letter defending ex-President Jair Bolsonaro, calling his trial “a witch hunt” and accusing Brazil of censorship and unfair trade. “Brazil has treated Bolsonaro disgracefully,” Trump wrote, adding that the tariffs are just the beginning. A Section 301 investigation into Brazil’s digital trade practices is also underway. Trump hinted at possible revisions if Brazil reforms, but warned of further hikes otherwise. #USBrazilTensions #TrumpTariffs #Geopolitics #JairBolsonaro #TradeWar Trump Threatens 200% Pharma Tariff, India Alarmed Trump is now eyeing a 200% tariff on pharmaceutical imports, a move that could hit India’s $30 billion pharma exports hard. The threat follows a Section 232 probe launched in April into whether pharma imports pose a national security risk. The U.S. accounts for 31% of Indian pharma exports and sources nearly 40% of its generics from India. Indian manufacturers warn this could worsen drug shortages in the U.S. and disrupt patient care. “Adding tariffs will hurt patients and delay our investments in the U.S.,” said Kathleen Jaeger of the Indian Pharmaceutical Alliance. The final decision is expected soon, and Indian pharma companies are already weighing exit strategies. #PharmaTariffs #IndianPharma #GenericDrugs #TrumpTrade #DrugShortage New US Visa Fee Raises Travel Costs Planning a U.S. trip? Brace for a higher bill. Under Trump’s “One Big Beautiful Bill Act,” a new $250 Visa Integrity Fee is in effect for most non-immigrant visas including B1/B2 (tourist/business), F and M (student), H-1B (work), and J (exchange). The fee, described as a refundable “good behavior bond”, is meant to enforce compliance with visa terms—no overstaying or unauthorized work. Starting in 2026, the fee will rise annually with inflation. For Indian travelers, it means the cost of a U.S. tourist visa jumps from $185 to $472 (~₹40,500). Refunds are rare and only apply to those who strictly follow the rules. #USVisaFee #ImmigrationPolicy #H1B #TravelCosts #VisaNews Vedanta Under Fire: “Ponzi Scheme” Allegation Viceroy Research, the short-seller that exposed Wirecard, is now targeting Anil Agarwal’s Vedanta Resources. In a damning report, Viceroy labeled the Indian conglomerate a “Ponzi scheme,” citing mismanagement and unsustainable debt. Vedanta has denied the charges, calling them “malicious and baseless.” But co-founder Fraser Perring warned more reports are coming. Viceroy, known for its multi-report takedowns, has a track record of triggering steep stock declines—80% of its targets have suffered. Perring also disclosed that he and his team shorted Vedanta bonds in April. With more revelations likely, investor anxiety is growing. #Vedanta #ViceroyResearch #ShortSelling #FraserPerring #MarketWatch India Scrambles After China Cuts Fertiliser Exports Commerce Minister Piyush Goyal has warned of the risks of overdependence on China for fertiliser supplies, following Beijing’s export curbs on Di-ammonium phosphate (DAP)—India’s second-most used fertiliser. India imported over 2.5 million tonnes of DAP in FY25, much of it from China. The restrictions have spiked global prices and sparked fears of shortages during the kharif sowing season. Goyal called for diversified sourcing, domestic production boosts, and long-term mineral partnerships. He also projected India’s agri-exports could grow from ₹4.5 trillion to ₹20 trillion with better processing and branding. But the short-term focus remains: ensuring farmers have what they need to plant. #FertiliserCrisis #ChinaCurbs #PiyushGoyal #AgriExports #DAPShortage Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    8 分
  • Trump Targets BRICS | Another Medal for Modi | India’s Warship Power Play | Apple’s New COO: Sabih Khan

    Trump Targets BRICS | Another Medal for Modi | India’s Warship Power Play | Apple’s New COO: Sabih Khan
    2025/07/09
    Welcome to Top of the Morning by Mint.. I’m Nelson John and here are today’s top stories. “We Want a Deal, Not a Steal” — India Holds Firm on Trade India and the US have pushed their trade deal deadline from July 9 to mid-July, even as President Trump enforces steep retaliatory tariffs on 14 other nations. India, however, isn’t on that list yet. The deal is awaiting Trump’s final sign-off, but Indian negotiators are in no rush. “Vietnam signed too quickly—we’re drawing red lines,” said a senior official, referring to contentious issues like agriculture, dairy, GM seeds, and digital trade. India currently faces a 26% tariff, and with Trump’s August 1 tariff trigger looming, the stakes are high. Trade experts warn these deals reflect pressure, not parity. Apple’s New Ops Boss is India-Born Sabih Khan After nearly 30 years behind the scenes, Apple veteran Sabih Khan has been named Chief Operating Officer, taking over from Jeff Williams. Born in Moradabad, Khan moved from Singapore to the US, earning degrees in economics and mechanical engineering. Joining Apple in 1995, he’s been instrumental in shaping its global supply chain, driving sustainability, and expanding US manufacturing. CEO Tim Cook praised Khan’s values-driven leadership, calling him “a brilliant strategist” and “central architect of Apple’s supply chain.” Khan officially steps into the role later this month. India’s Warship Surge to Counter China India is arming up at sea. Over the next year, the Navy will induct six homegrown stealth frigates—Udaygiri, Taragiri, Mahendragiri, Himgiri, Dunagiri, and Vindhyagiri—under Project 17A. These 6,670-tonne vessels, with 75% indigenous content, are armed with BrahMos missiles and cutting-edge tech. The ₹45,000-crore project marks a significant upgrade over earlier Shivalik-class ships. INS Udaygiri has already been delivered, and the rest will follow by August 2026. PM Modi, at a rare tri-commissioning earlier this year, called it a step toward a self-reliant Navy. By 2047, the Navy aims to be fully ‘atmanirbhar’ with 60 warships under construction. Modi Bags Brazil’s Top Civilian Honour In Brazil, PM Modi was awarded the Grand Collar of the National Order of the Southern Cross—the country’s highest civilian honour—for deepening India-Brazil ties and advancing global cooperation. “This is a moment of immense pride for 140 crore Indians,” Modi said, calling President Lula the “architect” of the strategic partnership. This is Modi’s 26th international award since 2014. Just days earlier, he received Trinidad and Tobago’s top honour—the Order of the Republic—making him the first foreign leader to earn it. Trump Targets BRICS with 10% Tariff Threat Donald Trump has launched a fresh broadside against BRICS. Calling the bloc an attempt to “destroy the dollar,” Trump warned that all BRICS nations—including India—will face a 10% tariff if he returns to office. “If they want to play games, I can play too,” he said. Trump claimed BRICS is not a “serious threat,” but accused it of trying to dethrone the dollar as the world’s standard. He slammed President Biden’s handling of the dollar’s global status, saying losing it would be like “losing a world war.” Trump added, “The dollar is king. We’re going to keep it that way.” Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    8 分

Top of the Morningに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。